Search Results
Cerca in questo sito
548 risultati trovati con una ricerca vuota
- Adalvo acquires Enzene romiplostim biosimilar programme targeting global Nplate market
Adalvo has acquired Enzene's romiplostim biosimilar programme, expanding its complex biologics portfolio with a candidate referencing Nplate for immune thrombocytopenia. The agreement transfers the romiplostim biosimilar programme to Adalvo while Enzene remains responsible for development and manufacturing support, including preparation for potential regulatory submissions in the United States, Europe and other markets. The acquisition targets a reference medicine reported to have generated approximately $1.5 billion in global sales in 2025, although transaction consideration was not disclosed and the biosimilar has not received a new US or EU approval through this announcement. Field Content Article Type Deals Acquirer Adalvo Programme Seller Enzene Deal Type Biosimilar development programme acquisition Announcement Date 27 October 2026 Acquired Programme Romiplostim biosimilar programme Reference Medicine Nplate Reference Active Ingredient Romiplostim Therapeutic Area Haematology Target Indication Immune thrombocytopenia Product Category Investigational biosimilar Development and Manufacturing Partner Enzene Partner Responsibilities Continued development and manufacturing support Prospective Regulatory Markets United States; European Union; other international markets Regulatory Status Future regulatory submissions anticipated; no new US or EU biosimilar approval announced Acquisition Consideration Not disclosed Reference Product Global Sales Approximately $1.5 billion in 2025 according to the companies Manufacturing Geography India What Happened Adalvo acquired Enzene's romiplostim biosimilar programme while retaining Enzene as development and manufacturing partner. Why It Matters The transaction expands Adalvo's biosimilars portfolio into a complex biological treatment area with an established reference medicine market. Strategic Rationale Develop a biosimilar alternative to romiplostim for international markets using Enzene's development and manufacturing capabilities. Commercial Context The companies reported approximately $1.5 billion in 2025 global sales for the reference medicine. Key Takeaway Adalvo has acquired an investigational romiplostim biosimilar programme, not an approved biosimilar product; financial terms remain undisclosed. What to Watch Development milestones, comparability studies, regulatory submissions, manufacturing readiness and future commercial partnerships. Primary Source Enzene Primary Source URL https://www.enzene.com/news/adalvo-expands-biosimilars-portfolio-through-acquisition-of-romiplostim-biosimilar-programme-from-enzene/ Relevant Date 27 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- SynAct Pharma signs Brazilian resomelagon dengue partnership with Hipolabor on 50-50 profit-sharing terms
SynAct Pharma has formalised a Brazilian partnership with Hipolabor to develop and commercialise investigational resomelagon for dengue treatment under a 50-50 cost and profit-sharing structure. The definitive agreement follows an August term sheet and provides for equal sharing of development costs and future commercial profits from resomelagon in the Brazilian dengue market. The arrangement also includes sales milestone payments linked to cumulative net sales of $200 million, with payment amounts undisclosed, while SynAct retains rights outside the specified indication and territory. Field Content Article Type Deals Companies SynAct Pharma; Hipolabor Deal Type Definitive co-development and commercialisation agreement Announcement Date 27 October 2026 Previous Agreement Stage Term sheet announced in August 2026 Development Asset Resomelagon Therapeutic Area Infectious diseases Target Indication Dengue Territory Brazil Development Cost Sharing 50% SynAct Pharma; 50% Hipolabor Future Commercial Profit Sharing 50% SynAct Pharma; 50% Hipolabor Sales Milestone Structure Milestone payments linked to cumulative net sales of $200 million Sales Milestone Payment Amounts Not disclosed Upfront Payment Not disclosed Rights Outside Territory Retained by SynAct Pharma outside the agreed territory and indication Product Regulatory Status Investigational; no dengue treatment approval established by this agreement What Happened SynAct Pharma and Hipolabor signed a definitive agreement to co-develop and commercialise resomelagon for dengue in Brazil. Why It Matters The partnership establishes a regional development and commercialisation framework for an investigational dengue therapy, sharing both financial risk and potential returns. Strategic Rationale Combine SynAct's development asset with Hipolabor's Brazilian market capabilities while sharing programme costs and commercial profits equally. Financial Structure Equal cost and profit sharing plus sales milestone payments; milestone amounts were not disclosed. Key Takeaway SynAct and Hipolabor have formalised a Brazil-specific dengue partnership with 50-50 economic sharing, but resomelagon remains investigational. What to Watch Clinical development plans, Brazilian regulatory interactions, programme financing, potential marketing authorisation and future sales milestones. Primary Source SynAct Pharma Primary Source URL https://www.synactpharma.com/en/?p=27624 Relevant Date 27 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA approves Novo Nordisk Awiqli as first once-weekly basal insulin for children with type 2 diabetes
The FDA has expanded Novo Nordisk's Awiqli approval to children aged 10 years and older with type 2 diabetes, establishing the first once-weekly basal insulin option for this paediatric population. Awiqli (insulin icodec-abae) is now authorised as a once-weekly subcutaneous basal insulin for eligible children with type 2 diabetes as an adjunct to diet and exercise, extending its previously approved adult indication. The paediatric decision was supported by pharmacokinetic data from 18 patients and pharmacometric modelling, providing an additional insulin administration option that may reduce injection frequency compared with daily basal insulin regimens. Field Content Article Type Approvals Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Paediatric indication expansion Approval Announcement Date 23 October 2026 Company Novo Nordisk Drug Name Awiqli Generic Name Insulin icodec-abae Drug Class Long-acting basal insulin Therapeutic Area Endocrinology; diabetes Approved Indication Type 2 diabetes mellitus in children aged 10 years and older as an adjunct to diet and exercise Patient Population Paediatric patients aged 10 years and older with type 2 diabetes Administration Route Subcutaneous injection Dosing Frequency Once weekly Regulatory Significance First once-weekly insulin approved for paediatric type 2 diabetes in the United States Previous Approved Population Adults with type 2 diabetes Supporting Evidence Paediatric pharmacokinetic data and pharmacometric modelling Paediatric Pharmacokinetic Study Population 18 patients Comparative Efficacy Results Not provided in supplied summary Geography United States What Happened The FDA expanded Awiqli's approved use to children aged 10 years and older with type 2 diabetes. Why It Matters The decision introduces a once-weekly basal insulin option for eligible paediatric patients and may reduce treatment administration burden. Clinical Evidence The paediatric approval was supported by pharmacokinetic observations in 18 patients and pharmacometric modelling. Regulatory Distinction This is a new paediatric indication rather than a repeat of the existing adult approval. Key Takeaway Awiqli is the first FDA-approved once-weekly basal insulin for children aged 10 years and older with type 2 diabetes. What to Watch Updated paediatric prescribing guidance, dosing implementation, clinician adoption, reimbursement and real-world safety outcomes. Primary Source U.S. Food and Drug Administration Primary Source URL https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-once-weekly-insulin-type-2-diabetes-mellitus-pediatric-patients Relevant Date 23 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Corxel agrees $377 million SPAC combination with Amanat to fund oral obesity drug development
Corxel Pharmaceuticals US has agreed to merge with Amanat Acquisition Corp in a SPAC transaction expected to provide approximately $377 million in gross proceeds for its oral obesity drug pipeline. The proposed business combination includes a committed approximately $300 million private investment in public equity and is intended to finance Phase III development of CX11, an investigational oral small-molecule GLP-1 receptor agonist for obesity. Assuming no shareholder redemptions, the transaction is expected to support operations through 2029, with completion anticipated in the first half of 2027 subject to shareholder approvals and other closing conditions. Field Content Article Type Deals Companies Corxel Pharmaceuticals US; Amanat Acquisition Corp Deal Type Definitive SPAC business combination agreement Transaction Status Announced; not yet completed Announcement Date 26 October 2026 Target Company Corxel Pharmaceuticals US SPAC Partner Amanat Acquisition Corp Expected Gross Proceeds Approximately $377 million assuming no shareholder redemptions Committed PIPE Financing Approximately $300 million PIPE Meaning Private investment in public equity Transaction Valuation Not confirmed in supplied summary Acquisition Consideration Not specified; expected gross proceeds are not acquisition consideration Lead Development Asset CX11 Therapeutic Modality Oral small-molecule GLP-1 receptor agonist Therapeutic Area Metabolic disease; obesity Target Indication Obesity Planned Development Phase III clinical development Expected Operating Runway Through 2029 Expected Transaction Closing First half of 2027 Closing Conditions Subject to shareholder approvals and other customary closing conditions What Happened Corxel Pharmaceuticals US and Amanat Acquisition Corp announced a definitive agreement for a proposed SPAC business combination. Why It Matters The transaction could provide substantial capital to advance an oral GLP-1 obesity treatment through late-stage clinical development. Strategic Rationale Access public-market capital to fund CX11 development and establish a publicly listed obesity-focused biopharmaceutical company. Financial Structure Approximately $377 million in expected gross proceeds includes a committed approximately $300 million PIPE; proceeds depend on transaction assumptions. Key Takeaway The proposed merger could finance Corxel's obesity pipeline into 2029, but completion and the full expected proceeds remain conditional. What to Watch Shareholder approvals, redemption levels, transaction closing, final financing proceeds and CX11 Phase III initiation. Primary Source Corxel Pharmaceuticals US and Amanat Acquisition Corp via GlobeNewswire Primary Source URL https://www.globenewswire.com/news-release/2026/10/26/3387902/0/en/corxel-us-and-amanat-acquisition-corp-announce-definitive-business-combination-agreement-to-create-publicly-listed-obesity-focused-biopharmaceutical-company.html Relevant Date 26 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- nuaxia launches verified global database of 6.4 million profiled healthcare professionals
New global resource combines HCP reach with independently sourced specialty and specialism intelligence nuaxia has announced the development of a global database of more than 6.4 million contactable healthcare professionals across 249 countries and territories. Every HCP is profiled with core professional information including country of practice and specialty, together with detailed clinical specialisms where these can be established. Unlike traditional approaches that rely heavily on self-declared information, nuaxia builds its professional profiles from independent and authoritative sources. Peter Chopra, Founder and CEO of nuaxia, said: “Knowing somebody is a genuine doctor is not enough. You also need good evidence that they are the right doctor for the question you are asking. “Research recruitment still relies heavily on asking people to declare that they meet the criteria required to participate. But asking a question does not make the answer true. “That matters because the consequences can be significant. Independent testing by NewtonX has shown differences of 20–30% between results from verified and unverified professional samples, while the wider research industry continues to report substantial levels of fraudulent and poor-quality participation. “Our approach is to do more of the work before the HCP is ever contacted: identify the people who appear relevant from independently sourced professional evidence, rather than repeatedly asking them to prove who they are and what they do.” The approach is intended both to strengthen audience selection and improve the experience of healthcare professionals participating in research. “Doctors are not simply units of sample,” Chopra added. “They are the pharmaceutical industry’s customers, partners and clinical stakeholders. Better data should allow us to treat their time with considerably more respect.” The database also links HCPs to approximately 2.1 million healthcare organisations globally and provides the data foundation for nuaxia’s wider healthcare intelligence capabilities. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- European Commission approves Tecvayli monotherapy from first relapse in multiple myeloma
The European Commission has approved Johnson & Johnson's Tecvayli monotherapy from first relapse in multiple myeloma, moving the bispecific antibody into an earlier treatment setting. Tecvayli (teclistamab) is now authorised in the European Union as monotherapy for adults with relapsed or refractory multiple myeloma after at least one prior therapy, expanding its use beyond later-line treatment. In the Phase III MajesTEC-9 study, teclistamab reduced the risk of disease progression or death by 71% and the risk of death by 40% compared with standard-of-care regimens, supporting its use from the second-line setting. Field Content Article Type Approvals Regulatory Authority European Commission Regulatory Decision Marketing authorisation indication extension Announcement Date 23 October 2026 Company Johnson & Johnson Drug Name Tecvayli Generic Name Teclistamab Therapeutic Modality Bispecific antibody Therapeutic Area Haematology; oncology Approved Indication Monotherapy for adults with relapsed or refractory multiple myeloma after at least one prior therapy Patient Population Adults with relapsed or refractory multiple myeloma Minimum Prior Treatment At least one prior therapy Treatment Setting From first relapse; second-line and later Treatment Regimen Tecvayli monotherapy Supporting Clinical Study Phase III MajesTEC-9 Comparator Standard-of-care regimens Progression or Death Risk Reduction 71% relative risk reduction Death Risk Reduction 40% relative risk reduction Geography European Union Previous Regulatory Context Tecvayli was previously authorised in later-line multiple myeloma settings; this monotherapy extension is distinct from the Tecvayli plus daratumumab approval What Happened The European Commission expanded Tecvayli's monotherapy indication to adults with relapsed or refractory multiple myeloma after at least one prior treatment. Why It Matters The decision makes a bispecific antibody treatment option available earlier in the European multiple myeloma care pathway. Clinical Evidence MajesTEC-9 reported a 71% reduction in progression or death risk and a 40% reduction in death risk versus standard-of-care regimens. Key Takeaway Tecvayli monotherapy can now be used from first relapse in eligible EU patients, supported by Phase III evidence. What to Watch European reimbursement decisions, treatment sequencing, specialist centre adoption, safety management and long-term outcomes. Primary Source Johnson & Johnson Innovative Medicine Primary Source URL https://www.jnj.com/innovativemedicine/emea/media-center/press-releases/european-commission-approves-johnson-johnsons-tecvayli-teclistamab-monotherapy-for-relapsed-refractory-multiple-myeloma-expanding-treatment-options-from-first-relapse Relevant Date 23 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- China approves Bio-Thera BAT2306 as world's first secukinumab biosimilar
China has approved Bio-Thera's BAT2306 as the first secukinumab biosimilar authorised by a major regulator worldwide, opening a new biosimilar competition category. Bio-Thera's BAT2306, marketed as YOUZHUOMEI, has received approval from China's National Medical Products Administration as a biosimilar to secukinumab for psoriasis, ankylosing spondylitis and psoriatic arthritis. The company identifies the decision as the first major-regulator approval of a secukinumab biosimilar, creating a new potential treatment alternative across three immune-mediated inflammatory conditions. Field Content Article Type Approvals Regulatory Authority China National Medical Products Administration Regulatory Decision Biosimilar marketing approval Company Bio-Thera Solutions Product Development Code BAT2306 Brand Name YOUZHUOMEI Reference Medicine Secukinumab Product Type Biosimilar monoclonal antibody Therapeutic Area Immunology; inflammatory diseases Approved Indications Psoriasis; ankylosing spondylitis; psoriatic arthritis Approval Geography China Regulatory Significance Reported by Bio-Thera as the first secukinumab biosimilar approved by a major regulator worldwide Approval Announcement Date 22 October 2026 English Announcement Date 26 October 2026 Clinical Evidence Specific comparative clinical study results not provided in supplied summary Commercial Launch Timing Not confirmed in supplied summary Pricing Not disclosed What Happened China's NMPA approved Bio-Thera's BAT2306 as a secukinumab biosimilar for three inflammatory conditions. Why It Matters The approval introduces a biosimilar competitor to secukinumab and could support broader treatment access and price competition in China. Market Significance Bio-Thera describes BAT2306 as the world's first secukinumab biosimilar authorised by a major regulatory authority. Key Takeaway BAT2306 has obtained Chinese marketing approval for psoriasis, ankylosing spondylitis and psoriatic arthritis; international authorisations are not established by this decision. What to Watch Commercial launch, pricing, reimbursement, physician uptake, supply availability and regulatory filings in other markets. Primary Source Bio-Thera Solutions Primary Source URL https://www.bio-thera.com/news/1001462.html Relevant Date 22 October 2026; English announcement 26 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA approves Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer
The FDA has approved Pfizer's Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer, expanding the combination into an earlier treatment setting. The approval authorises Talzenna (talazoparib) with Xtandi (enzalutamide) for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer whose tumours harbour homologous recombination repair gene mutations identified using an FDA-authorised test. The decision was supported by the Phase III TALAPRO-3 study involving 599 patients and extends the combination's use beyond its previously authorised metastatic castration-resistant prostate cancer indication. Field Content Article Type Approvals Regulatory Authority U.S. Food and Drug Administration Regulatory Decision New indication approval Approval Date 26 October 2026 Company Pfizer Approved Combination Talzenna plus Xtandi Active Ingredients Talazoparib; enzalutamide Drug Classes PARP inhibitor; androgen receptor inhibitor Therapeutic Area Oncology; prostate cancer Approved Indication Metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations Patient Population Adults with eligible HRR-mutated metastatic prostate cancer Biomarker Homologous recombination repair gene mutations Biomarker Testing FDA-authorised test Supporting Clinical Study Phase III TALAPRO-3 Study Enrollment 599 patients Efficacy Results Specific efficacy estimates not provided in supplied summary Previous Approved Setting Metastatic castration-resistant prostate cancer New Treatment Setting Earlier metastatic androgen pathway modulation-naïve or -sensitive disease Geography United States What Happened The FDA approved talazoparib with enzalutamide for adults with HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. Why It Matters The approval expands access to a biomarker-directed PARP inhibitor combination earlier in the metastatic prostate cancer treatment pathway. Clinical Evidence The Phase III TALAPRO-3 study enrolled 599 patients; detailed efficacy outcomes were not included in the supplied summary. Key Takeaway Talzenna plus Xtandi now has an additional US indication for selected HRR-mutated metastatic prostate cancers beyond the castration-resistant setting. What to Watch Updated prescribing information, biomarker testing uptake, clinical guideline integration, reimbursement and real-world outcomes. Primary Source U.S. Food and Drug Administration Primary Source URL https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive Relevant Date 26 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA approves at-home subcutaneous Skyrizi induction for adults with Crohn's disease
The FDA has approved an at-home subcutaneous induction regimen for AbbVie's Skyrizi in Crohn's disease, offering an alternative to intravenous treatment initiation. Adults with moderately to severely active Crohn's disease can now begin Skyrizi (risankizumab-rzaa) treatment through an approved subcutaneous induction regimen using an on-body injector, rather than relying exclusively on intravenous induction. The Phase III AFFIRM study demonstrated superior clinical remission and endoscopic response at week 12 versus placebo, supporting the additional administration option for eligible patients. Field Content Article Type Approvals Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Approval of an additional administration regimen Announcement Date 23 October 2026 Company AbbVie Drug Name Skyrizi Generic Name Risankizumab-rzaa Therapeutic Area Gastroenterology; inflammatory bowel disease Approved Indication Moderately to severely active Crohn's disease in adults New Administration Option Subcutaneous induction Delivery Device On-body injector Treatment Location At-home induction for eligible patients Previous Induction Route Intravenous infusion Supporting Clinical Study Phase III AFFIRM Clinical Endpoints Clinical remission and endoscopic response at week 12 Reported Study Outcome Superior clinical remission and endoscopic response versus placebo Numerical Efficacy Results Not provided in supplied summary Geography United States What Happened The FDA approved a subcutaneous induction regimen for Skyrizi in adults with moderately to severely active Crohn's disease. Why It Matters The new administration option may reduce dependence on infusion-centre visits during treatment initiation and improve convenience for eligible patients. Clinical Evidence AFFIRM demonstrated superior clinical remission and endoscopic response at week 12 compared with placebo. Key Takeaway Skyrizi now offers an FDA-approved at-home subcutaneous induction option for Crohn's disease, distinct from its established intravenous induction regimen. What to Watch Prescribing information, payer coverage, device training, patient uptake, adherence and real-world treatment outcomes. Primary Source AbbVie via PR Newswire Primary Source URL https://www.prnewswire.com/news-releases/us-fda-approves-subcutaneous-induction-regimen-for-abbvies-skyrizi-risankizumab-rzaa-for-adults-with-moderately-to-severely-active-crohns-disease-302918434.html Relevant Date 23 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Biocon expands Yesintek biosimilar licensing rights to nine additional international markets
Biocon has secured additional licensing rights for its Yesintek ustekinumab biosimilar across nine international markets, broadening its planned commercial footprint. The agreement with Janssen Sciences Ireland covers Yesintek, a proposed biosimilar to Stelara, in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan. The new rights extend Biocon's previously established market-entry arrangements, although financial terms were not disclosed and commercial launches remain dependent on applicable national regulatory approvals. Field Content Article Type Deals Companies Biocon; Janssen Sciences Ireland Deal Type International biosimilar licensing and market-entry agreement Licensee Biocon Licensing Counterparty Janssen Sciences Ireland Product Yesintek Active Ingredient Ustekinumab Reference Medicine Stelara Product Category Proposed biosimilar Therapeutic Area Immunology; immune-mediated inflammatory diseases Newly Covered Markets Australia; Brazil; China; Hong Kong; Israel; Mexico; New Zealand; South Korea; Kazakhstan Number of Additional Markets 9 Existing Market Context Previously secured market-entry rights in the United States and other major regions Financial Terms Not disclosed Upfront Payment Not disclosed Milestone Payments Not disclosed Royalties Not disclosed Regulatory Status Country-specific regulatory approvals remain necessary where applicable Commercial Launch Timing Not confirmed in supplied summary Announcement Date 26 October 2026 What Happened Biocon entered an agreement with Janssen Sciences Ireland expanding Yesintek market-entry rights to nine additional international territories. Why It Matters The agreement increases the potential geographic reach of Biocon's ustekinumab biosimilar and could support future biosimilar competition in additional markets. Strategic Rationale Expand Biocon's international biosimilar commercialisation opportunities through additional licensed territories. Regulatory Distinction The announcement concerns licensing and market-entry rights, not nine new marketing authorisations. Key Takeaway Biocon has secured Yesintek rights across nine additional markets, with actual commercialisation subject to national regulatory requirements. What to Watch Country-specific approvals, launch schedules, pricing, reimbursement decisions, supply arrangements and market uptake. Primary Source Biocon Primary Source URL https://www.biocon.com/biocon-secures-market-entry-for-yesintek-a-proposed-biosimilar-to-stelara-in-additional-global-markets/ Relevant Date 26 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Bolt Biotherapeutics acquires Prana Therapies alongside $120 million financing to advance inflammatory disease pipeline
Bolt Biotherapeutics has acquired Prana Therapies in a stock-for-stock transaction and arranged $120 million in financing to advance a new inflammatory disease pipeline. The acquisition adds Prana Therapies' INSPIRE multispecific antibody platform and lead candidate PRA-216, an investigational IL-4Rα/TSLP bispecific antibody in Phase II development for asthma, COPD and atopic dermatitis. Bolt separately arranged a $120 million private placement with the potential for up to $60 million in additional warrant proceeds, providing funding intended to support operations into 2028; these financing amounts are separate from the acquisition consideration. Field Content Article Type Deals Acquirer Bolt Biotherapeutics Acquired Company Prana Therapies Deal Type Stock-for-stock acquisition structured as a reverse merger Transaction Status Completed Announcement Date 23 October 2026 Acquisition Consideration Stock-for-stock; monetary valuation not specified in supplied summary Acquired Technology Platform INSPIRE multispecific antibody platform Lead Acquired Asset PRA-216 Therapeutic Modality Bispecific antibody Molecular Targets IL-4Rα and TSLP Therapeutic Area Immunology and inflammatory diseases Target Indications Asthma; chronic obstructive pulmonary disease; atopic dermatitis Development Stage Phase II Separate Financing $120 million private placement Potential Additional Financing Up to $60 million from warrant exercises Total Potential Financing Up to $180 million including contingent warrant proceeds Financing Versus Acquisition Consideration The private placement and potential warrant proceeds are separate financing arrangements and are not acquisition consideration Expected Cash Runway Into 2028, according to the supplied transaction summary Financing Purpose Support clinical development and company operations Geography Not specified in supplied summary What Happened Bolt Biotherapeutics acquired Prana Therapies in a stock-for-stock transaction and separately arranged a $120 million private placement. Why It Matters The acquisition adds a Phase II inflammatory disease candidate and a multispecific antibody platform, repositioning Bolt's development pipeline. Strategic Rationale Combine Prana's investigational immunology assets with Bolt's corporate and development infrastructure, supported by new financing. Pipeline Impact PRA-216 provides exposure to asthma, COPD and atopic dermatitis development programmes. Financial Impact The $120 million private placement and up to $60 million in potential warrant proceeds are intended to extend the company's operating runway into 2028. Key Takeaway Bolt has acquired a clinical-stage inflammatory disease pipeline through a stock transaction, while securing separate financing to support its development strategy. What to Watch PRA-216 Phase II clinical results, subsequent development plans, regulatory interactions, warrant exercises and the company's operating cash runway. Primary Source Bolt Biotherapeutics Primary Source URL https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-announces-acquisition-prana-therapies-and Relevant Date 23 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Menarini Stemline licenses Georgiamune GIM-621 oral cancer immunotherapy in deal worth up to $1.1 billion
Menarini's Stemline Therapeutics has secured worldwide rights to Georgiamune's investigational oral cancer immunotherapy GIM-621 in a licensing agreement worth up to $1.1 billion. The exclusive collaboration gives Stemline global development, manufacturing and commercialisation rights to GIM-621, a preclinical first-in-class oral small-molecule immunotherapy being investigated for multiple solid tumours. Georgiamune will receive $45 million in combined upfront and near-term payments and may earn additional preclinical, development, regulatory and commercial milestones, bringing potential consideration to $1.1 billion plus royalties. Field Content Article Type Deals Companies Menarini Group; Stemline Therapeutics; Georgiamune Deal Type Exclusive worldwide licensing and collaboration agreement Licensor Georgiamune Licensee Stemline Therapeutics, a Menarini Group company Licensed Asset GIM-621 Therapeutic Area Oncology Target Indications Multiple solid tumours under investigation Therapeutic Modality Oral small-molecule immunotherapy Asset Description Investigational first-in-class oral immuno-oncology agent Development Stage Preclinical Licensed Rights Global development, manufacturing and commercialisation Territory Worldwide Upfront and Near-Term Payments $45 million combined; individual amounts not disclosed Total Potential Deal Value Up to $1.1 billion plus royalties Additional Milestones Preclinical, development, regulatory and commercial milestones; individual amounts not disclosed Royalties Additional royalties; rates not disclosed Announcement Date 22 October 2026 What Happened Menarini subsidiary Stemline Therapeutics entered an exclusive global licensing and collaboration agreement for Georgiamune's GIM-621. Why It Matters The transaction adds a novel investigational oral immunotherapy programme to Menarini's oncology pipeline and provides Georgiamune with funding and potential downstream payments. Strategic Rationale Stemline gains worldwide rights to advance GIM-621 while Georgiamune benefits from a pharmaceutical development and commercialisation partner. Key Takeaway The agreement carries up to $1.1 billion in potential consideration plus royalties, but GIM-621 remains preclinical and most payments depend on future milestones. What to Watch Preclinical validation, investigational new drug preparation, first-in-human development, target indications and milestone achievements. Primary Source Menarini Group Primary Source URL https://www.menarini.com/en-us/news/news-detail/georgiamune-and-menarini-group-enter-exclusive-global-license-and-collaboration-agreement-for-gim-621-a-first-in-class-oral-immuno-oncology-agent.html Relevant Date 22 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com


